PLYX

Polaryx Therapeutics, Inc.distress 6/10 · elevated risk

$2.15-4%today-94% from 52w high

polaryx.com2 employeesFounded 2014Paramus, NJBiotechnology

Lead: multiple LSDs (CLN2

Revenue

pre-revenue

Liquidity

$3M

Runway

0.8 yrs

Shares 1y

Price & events

-93.9% over 6M

CatalystRating changeDilutionFinancingdashed = today

-4.0%

-6.9%

-10.8%

-59.6%

—

-93.9%

All

Overview

Market Cap: $101.79M
Volume: 1.03K
52 Week Range: $2.15 – $35.00
Total Shares: 47.34M
Float Shares: 4.28M
Short %: 1.89%
% Held by Insiders: 69.34%
% Held by Institutions: 4.55%
RVOL: 0.01x

Pipeline stages · 1 programs

PLX-200

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-12-31

Pipeline · 1 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-12-31 Estimated 50% readout ~2027-03-16	Phase 3	PLX-200fast track	Juvenile Neuronal Ceroid Lipofuscinosis	—	not yet recruiting

Catalyst news & presentations · 1

second half of 2026Guided 55%trial initiationsecondaryPhase 2PLX-200 · Initiation of Phase 2 SOTERIA basket trialSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 47,343,297 · 1 offerings/1y · 1 PIPEs

2026-05-288-Kprivate_placement
2026-02-02424B4offering
2026-01-29EFFECTshelf_effective
2026-01-27S-1/Ashelf_registration
2026-01-14S-1/Ashelf_registration
2025-11-21S-1shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $9 (+295% upside) · 2 analysts

2026-07-09HC Wainwright & Co.Buy
2026-02-27Maxim GroupBuy

Competitors — multiple LSDs (CLN2

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.